Population Pharmacokinetic Modelling for Estimation of Remifentanil Metabolic-Ratio Using Non-steady-State Concentrations Under Rapidly Adaptive Dosing

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2018 Sep 27

PMID 30255401

Authors

Monica Simeoni

Chao Chen

Affiliations

Soon will be listed here.

Abstract

Purpose: To predict steady-state metabolite-to-drug concentration ratio (metabolic ratio) for analgesic drug remifentanil, using sparse non-steady-state data from patients with normal or impaired renal function during individualised, highly variable and rapidly adaptive intravenous infusion.

Methods: A three-compartment joint parent-metabolite population pharmacokinetic model was developed using concentrations of remifentanil and its metabolite remifentanil acid from two trials. Renal function was included as an important mechanistic covariate. To address the large covariate effect and highly individualised and rapidly adaptive dosing, standardised visual predictive check was conducted on the observations and individualised visual predictive check was conducted on metabolic ratio estimates. The model was used to simulate metabolic ratio distribution in patients with various renal functions.

Results: The model, including its covariate structure, adequately described the data. The predictive checks allowed informative model evaluation. The predicted median (10th - 90th percentile) of remifentanil metabolic ratio was 12.5 (2.4-58.2) for patients with normal or mildly impaired renal function, or 54.3 (12.8-218.4) for patients with moderately or severely impaired renal function.

Conclusions: The methodologies applied here allowed robust estimation of steady-state parameters using non-steady-state sparse data under highly variable adaptive dosing.

References

Dershwitz M, Hoke J, Rosow C, Michalowski P, Connors P, Muir K . Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology. 1996; 84(4):812-20. DOI: 10.1097/00000542-199604000-00008. View

Bender J, van den Elshout J, Selinger K, Broeders G, Dankers J, van der Heiden C . Determination of remifentanil in human heparinised whole blood by tandem mass spectrometry with short-column separation. J Pharm Biomed Anal. 2000; 21(3):559-67. DOI: 10.1016/s0731-7085(99)00151-x. View

Hoke J, Shlugman D, Dershwitz M, Michalowski P, Connors P, Martel D . Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology. 1997; 87(3):533-41. DOI: 10.1097/00000542-199709000-00012. View

Breen D, Wilmer A, Bodenham A, Bach V, Bonde J, Kessler P . Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment. Crit Care. 2004; 8(1):R21-30. PMC: 420060. DOI: 10.1186/cc2399. View

Frame B, Miller R, Lalonde R . Evaluation of mixture modeling with count data using NONMEM. J Pharmacokinet Pharmacodyn. 2003; 30(3):167-83. DOI: 10.1023/a:1025564409649. View

Largajolli A, Bertoldo A, Campioni M, Cobelli C . Visual Predictive Check in Models with Time-Varying Input Function. AAPS J. 2015; 17(6):1455-63. PMC: 7583547. DOI: 10.1208/s12248-015-9808-7. View

Brendel K, Comets E, Laffont C, Laveille C, Mentre F . Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006; 23(9):2036-49. PMC: 2124466. DOI: 10.1007/s11095-006-9067-5. View

Brendel K, Comets E, Laffont C, Mentre F . Evaluation of different tests based on observations for external model evaluation of population analyses. J Pharmacokinet Pharmacodyn. 2009; 37(1):49-65. PMC: 2874574. DOI: 10.1007/s10928-009-9143-7. View

Wang D, Zhang S . Standardized visual predictive check versus visual predictive check for model evaluation. J Clin Pharmacol. 2011; 52(1):39-54. DOI: 10.1177/0091270010390040. View

10.

Lemenuel-Diot A, Laveille C, Frey N, Jochemsen R, Mallet A . Mixture modeling for the detection of subpopulations in a pharmacokinetic/pharmacodynamic analysis. J Pharmacokinet Pharmacodyn. 2006; 34(2):157-81. DOI: 10.1007/s10928-006-9039-8. View

11.

Bergstrand M, Hooker A, Wallin J, Karlsson M . Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13(2):143-51. PMC: 3085712. DOI: 10.1208/s12248-011-9255-z. View

12.

Carlsson K, Savic R, Hooker A, Karlsson M . Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making. AAPS J. 2009; 11(1):148-54. PMC: 2664892. DOI: 10.1208/s12248-009-9093-4. View

13.

Breen D, Karabinis A, Malbrain M, Morais R, Albrecht S, Jarnvig I . Decreased duration of mechanical ventilation when comparing analgesia-based sedation using remifentanil with standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial [ISRCTN47583497]. Crit Care. 2005; 9(3):R200-10. PMC: 1175879. DOI: 10.1186/cc3495. View

14.

Mentre F, Escolano S . Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J Pharmacokinet Pharmacodyn. 2005; 33(3):345-67. PMC: 1989778. DOI: 10.1007/s10928-005-0016-4. View

15.

Pitsiu M, Wilmer A, Bodenham A, Breen D, Bach V, Bonde J . Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. Br J Anaesth. 2004; 92(4):493-503. DOI: 10.1093/bja/aeh086. View

16.

Kapila A, Glass P, Jacobs J, Muir K, Hermann D, Shiraishi M . Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology. 1995; 83(5):968-75. DOI: 10.1097/00000542-199511000-00009. View

17.

Westmoreland C, Hoke J, Sebel P, HUG Jr C, Muir K . Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology. 1993; 79(5):893-903. DOI: 10.1097/00000542-199311000-00005. View